02nd April 2022 | Pharma Updates
Dr. Reddy's will invest Rs 463 crore for Novartis' heart medication Cidmus
Dr Reddy’s Laboratories, an Indian generic drugmaker, has agreed to pay $61 million to Novartis AG for the cardiovascular brand Cidmus (approximately Rs 463 crore).
Mexico in talks to get Indian technology for vaccines and cancer drugs
Mexican Foreign Minister Marcelo Ebrard has began discussions with Indian companies about receiving medical technology to create vaccinations and cancer treatments in Mexico.
mRNA-based vaccination from Gennova will be postponed
The drug regulatory body has requested additional information from Pune-based Gennova Biopharmaceuticals, delaying the launch of its mRNA-based Covid-19 vaccine.
Biocon Biologics' Inpremzia receives a favourable opinion from the European Medicines Agency
European Medicines Agency’s CHMP has issued a favourable opinion, suggesting that Inpremzia, a biosimilar version of human insulin, be granted a marketing authorization.
Pfizer Covid vaccine reduced Omicron hospitalizations by 68% in children
Vaccination of children aged 5-11 years old reduced hospitalizations with Covid-19 by more than two-thirds during the Omicron outbreak and also protected against severe illness.
As per studies, 'hybrid immunity' provides the best COVID-19 protection
People who have “hybrid immunity, ” meaning they’ve been fully vaccinated and have been infected with Covid-19 before, have the most protection against the virus.
Prescriptions for benzodiazepines for veterans with PTSD decreased
As per retrospective observational study, benzodiazepine prescriptions for U.S. military veterans with PTSD dropped during a 10-year period due to decreasing prevalence.
Merck faces an FDA delay for a major paediatric usage
Merck seeks to gain a significant advantage over Pfizer in the next-generation pneumococcal vaccination competition by gaining paediatric approval for Vaxneuvance.
Yescarta approved by the USFDA as the first CAR T-cell therapy
FDA has approved Yescarta, CAR T-cell treatment for adult patients with large B-cell lymphoma, according to Kite, a Gilead Company.
COVID-19 Oral Antiviral Lagevrio (Molnupiravir, MK-4482) For 2022
Molnupiravir, originally intended to treat influenza, inhibits the replication of numerous RNA viruses, including SARS-CoV-2, the causative agent of COVID-19.